GT Biopharma (FRA:OXIA) Total Receivables: €0.00 Mil (As of Mar. 2026)


FRA:OXIA GT Biopharma Inc FRA:OXIA
28 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma Total Receivables?

GT Biopharma FRA:OXIA 28 Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:OXIA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

GT Biopharma's Total Receivables for the quarter that ended in Mar. 2026 was €0.00 Mil.

GT Biopharma Total Receivables Historical Data

* Premium members only.

The historical data trend for GT Biopharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma Total Receivables Chart

GT Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GT Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:OXIA
28GF Score
GT Biopharma Inc FRA:OXIA
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.00 Mil mean?
GT Biopharma (FRA:OXIA) has a Total Receivables of €0.00 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on GT Biopharma and its competitors.
Is GT Biopharma's Total Receivables too high?
GT Biopharma's current Total Receivables is €0.00 Mil. Overall, GT Biopharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's Total Receivables compare to INTI and HIND?
GT Biopharma's Total Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on GT Biopharma and its competitors. GT Biopharma's current Total Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (FRA:OXIA) has a current Total Receivables of €0.00 Mil. The current Total Receivables is €0.00 Mil. GT Biopharma's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For GT Biopharma (FRA:OXIA), the current Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
28GF Score

Get the complete analysis for FRA:OXIA

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price